Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)

Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents

The purpose of this study is to gain information on reticulocyte neocytolysis in patients treated with ESA with regard to different types of ESA.

Inclusion Criteria:

• signed informed consent
• age > 18 years, dialysis dependent chronic renal failure
• hemodialysis three times a week
• Kt/V > 1,2 od URR > 65%
• hemoglobin between 11 and 13 g/dl within the last 2 months
• hemoglobin change +/- 1g/dl within the last 4 weeks
• ESA for at least 8 weeks
• Ferritin > 300 ng/ml and Tsat > 25%

Exclusion Criteria:

• Significant bleeding in the last 8 weeks
• blood transfusion within the last 8 weeks
• hemoglobin disorder
• hemolysis
• Malignant disease
• Significant inflammation
• Acute infection
• CRP > 30 mg/l
• Temporary vascular dialysis access
• Vitamin B12 deficiency
• Folic acid deficiency
• Not controlled hyperparathyroidism
• Not controlled hypertension
• Epilepsia within thze last 6 months
• Thrombocyte count > 500 x 10^9 /l